Markets & Industry
Eastra Health appoints new chief scientist to lead women-focused research
Emeline Maillet will help develop psychedelics-derived treatments for menopause and PMS.
Psychedelics company Eastra Health has appointed a new chief scientific officer.
Emeline Maillet, a pharmacologist and neuroscientist with over 20 years of experiences, has an extensive track record in the field.
She has previously worked as scientific director for Eleusis, a psychedelics life science company, where she led research into HT2A-targeting drugs and new molecular entities.
Prior to that, she worked as a senior scientist at Coca-Cola and in the field of substance-related disorders at DemeRx.
Eastra Health’s CEO Jeremy Weate said: “We are thrilled to welcome Emeline as our CSO and senior leader within our organisation.
Emeline Maillet, chief scientific officer at Eastra Health.
“Only a few scientists in the psychedelics field possess the depth of knowledge she has as a pharmacologist and a neuroscientist.
“Emeline is a thought leader with the capability to deliver groundbreaking research that leads to safe and therapeutically beneficial psychedelic medicines that advance women’s healthcare.”
The company describes itself as ‘the world’s first female-focused biotech company dedicated to developing psychedelic-derived medicines designed for women’.
Eastra focuses on ‘under-addressed health challenges women face, from PMS to menopause, through an innovative approach to drug development and a deep understanding of women’s health’.
Maillet said: “Women’s health includes diseases and conditions which are unique to female biology.
“Unfortunately, these topics had been historically underrepresented in both scientific research and pharmaceutical development.
“Personally, I have found the medical system and pharmacotherapies proposed for women’s reproductive health, hormonal imbalances, wellbeing, and female-specific mental health conditions quite limited and, in certain instances, antiquated.
“At Eastra, my goal as CSO is to develop psychedelic-derived medicines that will serve as new tools and options within the pharmacotherapeutic arsenal for women’s health.”
[activecampaign form=1]